Table 3 Factors associated with serious adverse events determined by univariate and multivariate mixed-effects model analysis
Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
All procedures ( n = 632) | Serious adverse events YES ( n = 164) | Serious adverse events NO ( n = 468) | P | OR (95% CI) | P | |
Phase 1, n (%) | 184 (29%) | 68 (41%) | 116 (25%) | |||
Phase 2, n (%) | 129 (20%) | 36 (22%) | 93 (20%) | 0.09 | ||
Phase 3, n (%) | 170 (27%) | 29 (18%) | 141 (30%) | < 0.001 | 0.40 (0.23; 0.72) | < 0.01 |
Phase 4, n (%) | 149 (24%) | 31 (19%) | 118 (25%) | < 0.01 | 0.53 (0.30; 0.92) | 0.03 |
Age, median (IQR) | 63 (51; 71) | 64 (56; 75) | 62 (51; 70) | 0.09 | ||
Female gender, n (%) | 186 (29%) | 44 (27%) | 142 (30%) | 0.44 | ||
SAPS II, median (IQR) | 39 (29; 41) | 39 (31; 53) | 38 (28; 50) | 0.19 | ||
Surgical admission, n (%) | 219 (35%) | 104 (63%) | 309 (66%) | 0.54 | ||
Intubation status, n (%) | 216 (34%) | 79 (48%) | 137 (29%) | < 0.01 | 1.91 (1.28; 2.85) | < 0.01 |
Sustained use of sedatives, n (%) | 114 (18%) | 38 (23%) | 76 (16%) | 0.17 | ||
RASS level, median (IQR) | 0 (-1; 0) | 0 (-2; 0) | 0 (-1; 0) | 0.05 | ||
Pain during moving | ||||||
Moderate pain, n (%) | 160 (25%) | 41 (25%) | 119 (25%) | 0.81 | ||
Severe pain, n (%) | 61 (10%) | 30 (18%) | 31 (7%) | < 0.001 | 2.74 (1.54; 4.89) | < 0.001 |